Key result
Atorvastatin shows no difference versus rosuvastatin for MACE in ACS.
Why the study?
Statins are crucial in managing cholesterol and cardiovascular risk in ACS, but direct comparative studies between atorvastatin and rosuvastatin are limited.
Does atorvastatin compared to rosuvastatin reduce MACE and all-cause mortality in patients with acute coronary syndrome?
Meta-Analysis (n=4,195)
Yes
Does atorvastatin compared to rosuvastatin reduce MACE and all-cause mortality in patients with acute coronary syndrome?
Relative Risk: 0.91 (95% CI 0.68–1.22)
p-value: p=0.54
Atorvastatin and rosuvastatin demonstrate comparable efficacy in reducing major adverse cardiovascular events and all-cause mortality in patients with acute coronary syndrome.
Supports interchangeable atorvastatin or rosuvastatin use in ACS; confirms comparable MACE reduction in meta-analysis.
Acute coronary syndrome (ACS) remains a leading cause of morbidity and mortality worldwide. Statins, particularly atorvastatin, and rosuvastatin, are crucial in managing cholesterol levels and reducing cardiovascular risk in ACS patients. However, direct comparative studies between these two statins are limited. This meta-analysis aimed to compare the efficacy of atorvastatin and rosuvastatin in reducing major adverse cardiovascular events (MACE) and all-cause mortality in patients with ACS. A comprehensive literature search was conducted in PubMed, Embase, Cochrane Library, and Scopus for studies published up to July 2024. Randomized controlled trials and observational studies directly comparing atorvastatin and rosuvastatin in ACS patients were included. The primary outcomes were the incidence of MACE and all-cause mortality. Six studies involving 4195 patients were included in the meta-analysis. Pooled analysis showed no statistically significant difference between atorvastatin and rosuvastatin in reducing MACE [risk ratio (RR): 0.91, 95% confidence interval (CI): 0.68 to 1.22, p-value: 0.54] or all-cause mortality (RR: 0.94, 95% CI: 0.52 to 1.70, p-value: 0.83). No significant heterogeneity was observed among the studies (I-square: 0% for both outcomes). This meta-analysis suggests that atorvastatin and rosuvastatin have comparable efficacy in reducing MACE and all-cause mortality in ACS patients. These findings provide clinicians with flexibility in choosing between these statins based on individual patient factors. However, further large-scale randomized controlled trials are needed to confirm these results and explore potential differences in specific patient subgroups.
No takes yet. Share an insight, caveat, or question.
Shuja et al. (2024) conducted a meta-analysis in Acute Coronary Syndrome (n=4,195). Atorvastatin vs. Rosuvastatin was evaluated on Incidence of major adverse cardiovascular events (MACE) (RR 0.91, 95% CI 0.68 to 1.22, p=0.54). Atorvastatin showed no statistically significant difference compared to rosuvastatin in reducing major adverse cardiovascular events (RR 0.91) in patients with acute coronary syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: